Humanigen, Inc. - HGEN STOCK NEWS

Humanigen (NASDAQ: HGEN) reported a net loss of $30.1 million for Q2 2022, a significant improvement from $70.8 million in Q2 2021. Total cash and cash equivalents as of June 30, 2022, were approximately $47.0 million. The company has made strides in its clinical studies, increasing sites for the PREACH-M study in Australia and preparing to enroll in the RATinG study in the UK. Humanigen is also evaluating lenzilumab for various applications in oncology and COVID-19, aiming to accelerate development despite deemphasizing COVID-related efforts.

Humanigen, Inc. (Nasdaq: HGEN) announced preliminary topline results from NIAID's ACTIV-5/BET-B trial evaluating lenzilumab with remdesivir for hospitalized COVID-19 patients. The trial did not achieve statistical significance for its primary endpoint—patients alive and off mechanical ventilation by Day 29. There was a non-significant trend toward reduced mortality (HR 0.72). No new safety concerns related to lenzilumab were noted. CEO Cameron Durrant emphasized the need for further studies on treatments amid the ongoing COVID-19 challenges.

Humanigen, Inc. (HGEN) announced significant findings from the Phase 3 LIVE-AIR study of lenzilumab, highlighting its effectiveness in treating COVID-19 patients with elevated C-reactive protein (CRP) levels. Patients with baseline CRP <150 mg/L showed a 62% reduction in the risk of invasive mechanical ventilation or death when treated with lenzilumab compared to placebo. The likelihood of surviving without mechanical ventilation was 90% for those on lenzilumab, versus 79% for those receiving placebo. These results may support future Emergency Use Authorization from the FDA for lenzilumab.

Humanigen, Inc. (Nasdaq: HGEN) announced that the National Institute of Allergy and Infectious Diseases has completed the database lock for the Big Effect Trial of its lead drug candidate, lenzilumab, as part of the NIH's COVID-19 therapeutic initiative. This milestone allows for the completion of topline analysis, with results expected in July. Lenzilumab is being tested as a treatment for COVID-19 and is not yet approved. The study involves hospitalized patients and evaluates lenzilumab's safety and efficacy alongside remdesivir.

Humanigen, Inc. (NASDAQ: HGEN) has entered into an agreement with PCI Pharma Services to facilitate the importation and commercialization of lenzilumab in the UK, pending Conditional Marketing Authorization for COVID-19 treatment. PCI will purchase the drug for resale, enhancing Humanigen's supply chain readiness. Lenzilumab could save the National Health Service over £10,000 per patient and aims to address the ongoing COVID-19 hospitalizations in the UK, which exceed 235,000 this year. Further studies are planned to explore lenzilumab's efficacy in other conditions.

Humanigen, Inc. (NASDAQ: HGEN), a biopharmaceutical company, announced participation in various investor conferences in June 2022. Ken Trbovich, SVP Investor Relations, will present at the LD Micro Invitational XII on June 7, 2022. Cameron Durrant, CEO, will present at the Jefferies Global Healthcare Conference on June 10, 2022, and will join a virtual fireside chat at the Lytham Partners Summer 2022 Conference on June 21, 2022. The company focuses on lenzilumab for treating cytokine storm and various inflammatory conditions, continuing its development amidst ongoing clinical trials.

Humanigen, Inc. (NASDAQ: HGEN) announced that CEO Cameron Durrant will present at the H.C. Wainwright Global Investment Conference on May 23-26, 2022, in Miami, FL, at 11:00 am EDT. The presentation will update on the topline data release for ACTIV-5/BET-B and the company's plans for 2022. With over 1 million COVID-19 hospitalizations and 173,738 deaths in the U.S. this year, Humanigen emphasizes the need for additional therapeutics. A webcast of the event will be available on Humanigen's investor relations website for 90 days.

Humanigen, Inc. (NASDAQ: HGEN) provides an update on its lead drug candidate, lenzilumab, aimed at treating cytokine storm in COVID-19 patients. Key highlights include the completion of enrollment in the ACTIV-5/BET-B study and positive FDA feedback regarding an EUA amendment. Hospitalizations remain steady, with an average of 2,072 new cases daily. Financially, the company reported a net loss of $21.3 million for Q1 2022, a significant decrease from $65.6 million in Q1 2021, primarily due to reduced R&D expenses.